Overview

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Status:
COMPLETED
Trial end date:
2025-03-28
Target enrollment:
Participant gender:
Summary
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Phase:
PHASE2
Details
Lead Sponsor:
Biohaven Therapeutics Ltd.